This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.

Coverage of stories discussed this week on ascopost.com:

Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy

To listen to more podcasts from ASCO, visit asco.org/podcasts.